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A B S T R A C T
Introduction. Data on the effects of cross-sex hormone therapy (CHT) are limited due to the low prevalence of gender
dysphoria, small number of subjects treated at each center, lack of prospective studies, and wide variations in treatment
modalities.
Aim. The aim of this study is to report the short-term effects of CHT on hormonal and clinical changes, side effects,
and adverse events in trans men (female-to-male gender dysphoric persons) and trans women (male-to-female
gender dysphoric persons).
Methods. This was a multicenter 1-year prospective study in 53 trans men and 53 trans women. Trans men received
injections of testosterone undecanoate every 3 months. Trans women younger than 45 years received 50 mg
cyproterone acetate (CA) and 4 mg estradiol valerate daily, whereas those older than 45 years received 50 mg CA daily
together with 100 μg/24 hours transdermal 17-β estradiol.
MainOutcomeMeasures. Sex steroids, prolactin, liver enzymes, lipids, hematocrit, blood pressure, anthropometrics,
Ferriman and Gallwey score, and global acne grading scale were measured. Side effects, adverse events, and desired
clinical changes were examined.
Results. No deaths or severe adverse events were observed. Two trans men developed erythrocytosis, and two had
transient elevation of the liver enzymes. Trans men reported an increase in sexual desire, voice instability, and clitoral
pain (all P ≤ 0.01). Testosterone therapy increased acne scores, facial and body hair, and prevalence of androgenetic
alopecia. Waist–hip ratio, muscle mass, triglycerides, total cholesterol (C), and LDL-C increased, whereas total body
fat mass and HDL-C decreased. Three trans women experienced transient elevation of liver enzymes. A significant
increase in breast tenderness, hot flashes, emotionality, and low sex drive was observed (all P ≤ 0.02). Fasting insulin,
total body fat mass, and prolactin levels increased, and waist–hip ratio, lean mass, total C, and LDL-C decreased.
Conclusions. Current treatment modalities were effective and carried a low risk for side effects and adverse events at
short-time follow-up. Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher A, Toye K, Kaufman
JM, and T’Sjoen G. Cross-sex hormone therapy in trans persons is safe and effective at short-time
follow-up: Results from the European Network for the Investigation of Gender Incongruence. J Sex Med
2014;11:1999–2011.
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Introduction
Trans persons undergo cross-sex hormonetherapy (CHT) to induce the secondary sex
characteristics of the desired sex while reducing
those of the natal one [1]. The act of using cross-sex
hormones is also an affirmation of gender identity
in many trans persons. The choice of type and
dosage of hormones have not yet been established
as randomized controlled trials, and comparative
studies are lacking [2], and so, a variety of hormone
preparations are currently used [3]. Female-to-
male gender dysphoric persons, referred to as trans
men, are treated with testosterone (T) preparations
to induce virilization, sometimes preceded with
progestagens to suppress menstruation [1]. To
promote feminization, trans women (male-to-
female gender dysphoric persons) usually receive
estrogens in combination with antiandrogen
and/or gonadal axis suppression medication to
lower T levels and/or action [1].
Many centers in Europe use cyproterone
acetate (CA), a progestational agent with androgen
receptor-blocking properties [4–6], whereas spi-
ronolactone, a diuretic with antiandrogen action,
is mostly used in the United States [7,8]. Other
centers also use gonadotropin-releasing hormone
analogues [9,10], nonsteroidal androgen receptor
blockers, or 5-alpha reductase inhibitors. In addi-
tion, type of formulation, hormone dosage, and
route of administration (oral, transdermal, or
intramuscular) may differ between centers. These
wide variations in treatment modalities and the
low prevalence of transsexuality, and therefore
small number of subjects treated in each center,
hamper our knowledge on the effects and side
effects of CHT. Furthermore, hormonal therapies
have changed considerably in the past years, and
most current evidence is based on older treatment
regimens. The use of long-acting T preparations
has significantly increased in trans men, and the
use of ethinyl estradiol (EE) has decreased in trans
women due to the increased risk for cardiovascular
disease [11].
Aims
The aim of this study was to investigate the
physical and physiological effects, side effects,
and adverse events of commonly used CHTs.
We present the first multicenter prospective
study in a well-described cohort of trans persons
treated according to a standardized treatment
protocol.
Methods
Study Population and Sex Hormone Therapy
This research is part of the European Network
for the Investigation of Gender Incongruence
(ENIGI), a collaboration of four major West Euro-
pean gender identity clinics (Amsterdam, Ghent,
Hamburg, and Oslo) [12] created to study the diag-
nostics and treatment of gender dysphoria. We
present current data from the Department of
Endocrinology at the Ghent University Hospital
and the University Hospital in Oslo. All patients
diagnosed with gender dysphoria and referred to
our departments between February 2010 and
August 2012 were invited to participate in this
prospective study (N = 152). We included only
hormone-naive trans persons. After screening, by
thorough medical history and determination of
serum sex steroids, 44 individuals were excluded. A
total of 53 trans men and 53 trans women partici-
pated in our study (Figure 1). Patients were fol-
lowed every 3 months during the first treatment
year.
Trans men received injections of 1,000 mg
intramuscular T undecanoate (Nebido®, Bayer,
Germany) at the start of the study, after 6 weeks,
and every 12 weeks thereafter. Before T initiation,
progestagens were sometimes taken to suppress
the menstrual cycle. In case of nontolerance, injec-
tions with intramuscular T esters (T decanoate
100 mg, T isocaproate 60 mg, T fenylpropionate
60 mg, T propionate 30 mg/mL) (Sustanon
250®, MSD, Netherlands) every 2 weeks were
prescribed.
All trans women younger than 45 years (N = 40)
received 50 mg of CA (Androcur®, Bayer) in com-
bination with 4 mg of estradiol valerate (EV)
(Progynova®, Bayer) daily. Patients older than 45
years (N = 13) received 50 mg of CA daily in
combination with 100 μg/24 hours transdermal
17-β estradiol (E2) patch (Dermestril®, Besins,
Belgium). In case of nontolerance, 2 mg of trans-
dermal 17-β E2 gel twice daily (Oestrogel®, Besins)
or 4 mg EV per day was given. Based on the deci-
sion of the mental health professional and patient,
some trans women who favored a slower procedure
and/or needed an extra diagnostic evaluation
received a dual-phase protocol (N = 16). In the first
phase, sex-specific features were suppressed by
administration of CA 50 mg daily for about 3
months, and estrogens were added to induce femi-
nization in the second phase. This study complied
with the recommendations of the Declaration
of Helsinki and was approved by the ethical
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committee of the Ghent University Hospital and
the University Hospital of Oslo. All participants
gave written informed consent. Clinical trial
number: NCT01072825.
Main Outcome Measures
Medical History and Examination
Descriptive data were collected from all individu-
als, including physical and psychiatric medical
history, current and past medication use, familial
medical history, and lifestyle factors such as
smoking and alcohol consumption. Information
was compared with data from medical files for
accuracy and corrected if necessary.
Physical Parameters
Anthropometrics
Standing height was measured to the nearest
0.1 cm using a Harpenden stadiometer (Holtain
Ltd, Crymuch, UK). Body weight was measured in
light indoor clothing without shoes to the nearest
0.5 kg. Waist circumference, defined as the small-
est abdominal circumference, and hip circumfer-
ence, defined as the largest hip circumference,
were determined to the nearest 0.1 cm.
Body Composition
Whole body lean mass and fat mass were measured
using dual-energy X ray absorptiometry with
Hologic Discovery (Hologic Inc., Bedford, MA,
USA) in Belgium and with Lunar Prodigy Advance
(GE, Madison, WI, USA) in Norway.
Acne
Clinical assessment of acne was performed every 3
months in each patient by the same endocrinolo-
gist with the Gradual Acne Grading Scale (GAGS)
[13], a semiquantitative scoring system in which
the total severity score is derived from the
summary of six regional subscores. Each subscore
was obtained by the score of the most heavily
weighted lesion within each region (one for one or
more comedones, two for one or more papules,
three for one or more pustules, and four for one or
more nodules) multiplied by the factor for each
region (the factor for forehead and each cheek is 2,
chin and nose is 1, and chest and upper back is 3).
Figure 1 Subject enrollment
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Scores between 6 and 18, 20 and 30, and 31 and 36
were classified as mild, moderate, or severe acne,
respectively.
Body Hair and Distribution
The effects of T therapy on hair growth and dis-
tribution of body hair in trans men was evaluated
every 3 months using the modified Ferriman and
Gallwey classification [14] in each patient by the
same endocrinologist. This scale scores nine
androgen-dependent areas on a five-point Likert
scale (from 0 = no to 4 = very dense). A score for
an androgen-dependent area of more than 8 indi-
cated hirsutism. Androgenetic alopecia was
assessed using the Norwood/Hamilton classifica-
tion [15].
We were unable to evaluate the effects of CHT
on hair growth and distribution of body hair in
trans women because almost all of them under-
went laser epilation during the course of the study.
Side Effects and Adverse Events
Clinical adverse events, including cardiovascular
events, venous thrombosis and/or pulmonary
embolism, osteoporotic fractures, abnormal liver
function tests, hypertension, and death (including
suicide), were recorded. We also evaluated
whether hormone levels reached the target values
for the desired gender. Development of erythro-
cytosis, hyperprolactinaemia, hypercholesterol-
emia, and hyperglycemia was also assessed.
We evaluated symptoms possibly related to hor-
monal status every 3 months, including hot flashes,
night sweats, sleeping problems, fatigue, memory
or cognition problems, mood swings, irritability,
anxiety, low or high sexual desire, migraines, nail
and gum problems, breast tenderness, joint pain,
and muscle soreness using a four-point Likert scale
(no, mild, moderate, or severe complaints).
Biochemical Determinations
Venous blood was obtained at baseline and at 12
months, and serum was stored at −80°C until hor-
mones were analyzed in one batch. Blood samples
for routine clinical parameters were drawn at the
3-, 6-, and 9-month time points.
Luteinizing hormone (LH), follicle stimulating
hormone (FSH), sex hormone binding globulin
(SHBG), insulin, dehydroepiandrosterone sulfate
(DHEAS), and prolactin were measured by
electrochemiluminiscence immunoassay (ECLIA)
(Modular, Roche Diagnostics, Mannheim,
Germany). The interassay CVs were as follows:
LH 2.19%, FSH 2.55%, SHBG 2.8%, prolactin
4.8%, DHEAS 4.8%, insulin 2.3%. E2, estrone
(E1), DHEAS, androstenedione, cortisol, and T
were determined using liquid chromatography
tandem mass spectrometry (AB Sciex 5,500 triple-
quadrupole mass spectrometer; AB Sciex, Toronto,
Canada). The serum limit of quantification was
0.3 pg/mL for E2 and 0.5 pg/mL for E1, and the
interassay CVs were 4% at 21 pg/mL for E2 and
7.6% at 25 pg/mL for E1 [16]. Serum limit of
quantification was 1 ng/dL (35 pmol/L) for T, and
the interassay CV was 6.5% at 3 ng/dL. Hemoglo-
bin, hematocrit (Hct), glucose, creatinin, and the
liver enzymes glutamic-oxaloacetic transaminase
(AST), glutamic-pyruvic transaminase (ALT), cho-
lesterol (C), LDL-C, HDL-C, and triglycerides
were measured using routine clinical chemistry
methods.
Statistical Analysis
Descriptive statistics were expressed as means and
standard deviations, or medians [first to third
quartiles] for in case of a non-normal distributions.
Statistical analyses of categorical variables were
carried out using χ2 and Fisher’s exact tests as
appropriate. Statistics of means in prospective data
were carried out using the paired Student t-tests or
Wilcoxon signed-rank tests when variables were
not normally distributed. Between two groups,
statistics of means was evaluated using indepen-
dent Student t-tests and Mann–Whitney U-tests
when variables were not normally distributed. Sig-
nificance was set at P < 0.05 (two-tailed). Data
were analyzed using spss software, v.21 (SPSS Inc.,
Chicago, IL, USA). For all analyses, missing values
were excluded.
Results
General Characteristics
General characteristics of the study population are
shown in Table 1. Trans women were significantly
older than trans men at the time of presentation
(P < 0.001). A significantly greater proportion of
trans men were at the Oslo center, and the subjects
were significantly older at the Ghent center.
Hormonal and Biochemical Changes in Trans Men
All trans men achieved T levels within the male
reference range (321–1,005 ng/dL) during treat-
ment (Table 2). Three trans men (5.7%) had T
levels that exceeded the upper limit of 1,005 ng/dL
(one at 3-month, one at 9-month, and one at
12-month time point of treatment). Hct levels
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gradually increased during T treatment. Two trans
men developed erythrocytosis according to male
reference ranges (Hct levels above 52%), one
developed it after 9 months, and one after 12
months of treatment. T levels were within the
male reference range in these men. Erythrocytosis
was present in 20.1% of trans men according to
female reference ranges (Hct levels above 48%).
E2, E1, prolactin, and SHBG decreased signifi-
cantly, whereas DHEAS, androstenedione, and
cortisol levels were not influenced by T treatment.
T treatment induced a less favorable lipid profile,
as total C, LDL-C, and triglycerides increased,
whereas HDL-C decreased (Table 2).
Hormonal and Biochemical Changes in TransWomen
All trans women achieved adequate gonadotropin
and T suppression during antiandrogen and estro-
gen administration (Table 2). Two trans women
(both on oral EV) who initially had an adequate T
and gonadotropin suppression showed T levels
within the normal male range at 12 months, pos-
sibly due to poor adherence to treatment.
Gonadotropins, T, and androstenedione decreased
during oral and transdermal estrogen therapy
associated with CA, whereas E2 and E1 increased.
Trans women using oral EV, unlike those
using transdermal estrogen, experienced a signifi-
cantly increased SHBG, decreased DHEAS, and
a trend toward increased cortisol levels. Prolactin
levels significantly increased during both oral
and transdermal estrogen treatments (Figure 2A)
and during 12 weeks of CA treatment alone
(Figure 2B).
CHT induced a more favorable lipid profile as
total C and LDL-C decreased during both oral
and transdermal estrogen treatments. HDL-C
decreased during both forms of estrogen treatment,
and triglycerides decreased during transdermal but
not oral estrogen treatment. No significant differ-
ences were observed between trans women initially
treated with CA plus estrogens compared with
those initially treated with CA alone (data not
shown).
Physical Changes
Trans Men
Total body weight significantly increased due to an
increase in total lean mass, whereas total fat mass
decreased. An android pattern of fat distribution
was observed as the waist–hip ratio increased
during treatment (P = 0.02), mainly due to reduced
hip circumference (Table 3). As expected, Ferriman
and Gallwey score significantly increased (P <
0.001), with a wide between-subject variability
ranging from 2 to 28.
TransWomen
In contrast to trans men, total body weight
remained unchanged for trans women, although
they experienced an increase in total body fat mass
and a decrease in total body lean mass. A gynoid
pattern of fat distribution was induced in trans
women as the waist–hip ratio decreased during
treatment (Table 3).
Antiandrogen with estrogen treatment resulted
in a significant increase (average 3.3 cm) in breast
circumference at the nipple, with a wide inter-
individual range of increase. Trans women using
oral estrogens experienced similar changes in
physical measures as those using transdermal estro-
gens (Table 3). No significant differences were
observed between trans women treated with CA
plus estrogens from start compared with those ini-
tially treated with CA alone (data not shown),
although the former tended to have a larger breast
circumference (P = 0.06).
Side Effects and Adverse Events
Trans Men
We recorded no deaths, cardiovascular events,
osteoporotic fractures, venous thromboses, or
Table 1 Baseline characteristics of the study population
Trans men Trans women
Ghent (N = 27) Oslo (N = 26) Ghent (N = 47) Oslo (N = 6)
Age (years) 27.3 ± 8.5 21.7 ± 5.1 31.7 ± 14.8 19.3 ± 2.4
Current smoker (%) 25.9 14.4 19.1 0
Former smoker (%) 33.3 30.8 38.3 0
Alcohol (U/week) 0 (0–0) 0 (0–0.75) 0 (0–7) 0 (0–0)
Height (cm) 163.4 ± 4.4 168.3 ± 6.0 178.4 ± 6.2 179.5 ± 3.8
Weight (kg) 65.7 ± 15.0 71.2 ± 15.9 76.1 ± 13.9 73.7 ± 18.5
BMI (kg/m2) 24.5 ± 5.2 25.2 ± 5.5 23.9 ± 4.1 22.9 ± 5.7
Data are presented as mean ± standard deviation or median (first to third quartiles)
BMI = body mass index
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Table 2 Hormonal and biochemical changes in trans persons
Trans men (N = 53) Trans women (N = 53)
Intramuscular T
undecanoate
(N = 53) P
Oral
estrogens
(N = 40) P
Transdermal
estrogens
(N = 13) P
Testosterone (ng/dL)
Baseline 30.2 (20.4–39.9) <0.001 517.5 (419.2–631.9) <0.001 567.0 (484.8–678.2) 0.001
12 months 595.8 (481.1–715.7) 10.7 (8.3–14.3) 14.0 (12.4–17.2)
Estradiol (pg/mL)
Baseline 50.3 (24.2–99.3) 0.001 19.1 (15.3–24.9) <0.001 23.6 (18.3–29.3) 0.001
12 months 29.4 (21.7–34.7) 56.5 (42.3–70.8) 95.4 (58.5–127.6)
Estrone (pg/mL)
Baseline 51.7 (30.3–80.9) 0.01 29.8 (24.1–40.1) <0.001 45.8 (33.8–50.3) 0.028
12 months 45.5 (32.9–53.8) 360.9 (253.3–485.3) 57.8 (47.3–90.7)
SHBG (nmol/L)
Baseline 51.6 (23.0–81.2) <0.001 31.2 (24.0–40.1) <0.001 50.3 (36.0–59.7) 0.33
12 months 25.1 (19.7–34.0) 41.7 (25.8–50.7) 48.1 (29.0–90.7)
LH (U/L)
Baseline 6.7 (4.2–9.9) <0.001 4.8 (3.7–6.4) <0.001 5.5 (3.5–6.8) 0.001
12 months 2.4 (0.7–5.8) 0.1 (0.1–0.1) 0.1 (0.1–0.1)
FSH (U/L)
Baseline 4.8 (3.4–7.3) 0.02 3.5 (2.8–5.3) <0.001 5.4 (3.5–6.8) 0.001
12 months 4.2 (1.2–6.6) 0.2 (0.1–0.4) 0.2 (0.1–0.4)
Prolactin (ng/mL)
Baseline 13.7 (9.3–19.9) <0.001 8.1 (6.3–11.3) <0.001 6.6 (4.1–9.3) 0.001
12 months 9.6 (7.9–14.4) 20.6 (16.7–28.9) 26.2 (18.6–36.2)
DHEAS (μg/dL)
Baseline 254.0 (170.1–351.4) 0.97 289.9 (253.1–401.7) <0.001 285.9 (220.4–404.5) 0.42
12 months 257.6 (174.1–355.7) 236.8 (192.9–348.5) 275.6 (171.9–410.3)
Androstenedione (ng/dL)
Baseline 113.9 (90.9150.5) 0.42 101.2 (77.0–121.3) <0.001 117.4 (94.6–161.4) 0.001
12 months 113.8 (80.2–151.9) 56.2 (43.4–76.4) 69.6 (55.9–106.7)
Cortisol (μg/dL)
Baseline 13.3 (8.9–16.0) 0.42 15.2 (12.9–18.7) 0.06 15.4 (13.4–19.9) 0.28
12 months 11.8 (9.4–15.2) 15.7 (12.8–20.8) 15.0 (11.8–18.9)
Hematocrit (%)
Baseline 40.8 ± 2.9 <0.001 45.2 ± 2.5 0.003 45.5 ± 1.7 <0.001
12 months 45.8 ± 3.0 42.0 ± 5.7 42.0 ± 2.3
Fasting glucose (mg/dL)*
Baseline 0.80 ± 0.1 0.28 0.83 ± 0.1 0.78 0.92 ± 0.06 0.25
12 months 0.77 ± 0.1 0.84 ± 0.1 0.88 ± 0.1
Fasting insulin (mU/L)*
Baseline 9.1 (5.8–16.3) 0.02 7.2 (4.9–9.7) 0.019 7.3 (6.6–18.7) 0.1
12 months 7.5 (5.2–13.2) 9.3 (7.2–11.3) 12.0 (9.1–17.0)
Creatinin (mg/dL)
Baseline 0.74 ± 0.1 <0.001 0.9 ± 0.1 0.001 0.93 ± 0.1 0.011
12 months 0.84 ± 0.1 0.8 ± 0.1 0.85 ± 0.1
AST (U/L)
Baseline 20.0 (17–23) 0.01 24.1 ± 9.2 <0.001 26.8 ± 8.3 0.013
12 months 24 (18–29.5) 17.7 ± 3.6 19.6 ± 4.8
ALT (U/L)
Baseline 16.0 (11.5–20) 0.02 25.0 ± 17.4 0.01 29.9 ± 15.3 0.12
12 months 20 (15–25) 18.6 ± 9.5 21.0 ± 10.1
Total C (mg/dL)
Baseline 171.9 ± 28.1 0.04 171.5 ± 32.7 0.001 227.2 ± 35.6 0.004
12 months 178.2 ± 30.6 152.3 ± 28.3 181.3 ± 20.6
LDL-C (mg/dL)
Baseline 98.4 ± 26.3 0.006 99.4 ± 29.0 0.03 138.3 ± 24.8 0.001
12 months 116.1 ± 28.9 92.3 ± 28.9 106.3 ± 20.4
HDL-C (mg/dL)
Baseline 56.3 ± 12.7 <0.001 52.9 ± 13.5 <0.001 58.2 ± 15.2 0.26
12 months 47.8 ± 10.7 45.7 ± 9.2 54.8 ± 15.7
Triglycerides (mg/dL)
Baseline 69.0 (51.7–89.5) <0.001 79.5 (54.7–108) 0.1 87.0 (68.0–176.5) 0.03
12 months 81.1 (65.3–124.6) 70.8 (50–133.1) 85.0 (70.0–110)
*Based on subsample of trans women (N = 44) or trans men (N = 23)
Data are presented as mean ± standard deviation or median (first to third quartiles). P value results from paired t-test or Wilcoxon signed-rank test
ALT = glutamic-pyruvic transaminase; AST = glutamic-oxaloacetic transaminase; DHEAS = dehydroepiandrosterone sulfate; HDL-C = HDL cholesterol; LDL-
C = LDL cholesterol; FSH = follicle stimulating hormone; LH = luteinizing hormone; SHBG = sex hormone binding globulin
2004 Wierckx et al.
J Sex Med 2014;11:1999–2011
pulmonary embolisms in trans men. Two were
switched to short-acting intramuscular T esters
after 9 and 12 months, respectively, of T
undecanoate therapy mainly because of muscle
and joint aches. Liver enzymes increased during T
therapy, but only 1.9% of trans men had liver
enzymes values exceeding twice the upper limit of
normal according to female reference ranges. No
subject had liver enzymes values exceeding twice
the upper limit of normal according to male
reference ranges.
Blood pressure increased slightly during treat-
ment, but none of the subjects developed hyper-
tension during our observation. Fasting insulin
levels decreased (P = 0.02), and nobody developed
type 2 diabetes. GAGS acne scores increased
(P < 0.001), but the majority of trans men (94.3%)
had mild acne lesions. The remaining 5.7% had
moderate acne lesions after 12 months of therapy,
and no individuals had severe or very severe acne
lesions. Eighteen persons (34.0%) initiated topical
or oral acne treatment.
Seventeen percent of trans men developed
androgenetic alopecia. No indication of trouble-
some aggression, hostility, or sleep apnea was
present. All trans men reported loss of vaginal
bleeding during treatment. Spotting was reported
in about one-third of participants, generally limited
to the first 6 months of treatment (Figure 3).
TransWomen
Similar to trans men, no deaths, cardiovascular
events, osteoporotic fractures, venous thromboses,
or pulmonary embolisms were observed in trans
women. One trans woman had to stop estrogen
treatment due to major depression and was
excluded from our analyses. Serum prolactin levels
exceeding twice the upper limit of normal were
observed in 15.7% and 3.9% according to the male
and female reference range, respectively. One trans
woman experienced galactorea, which spontane-
ously stopped after several weeks. Transient eleva-
tion of the liver enzymes exceeding twice the upper
limit of normal was observed in 5.7% and 1.9%
according to the female and male reference ranges,
respectively. One trans woman developed hyper-
tension during the study observation (defined as a
systolic blood pressure above 140 mm Hg or
diastolic above 90 mm Hg at three different
time points). Fasting insulin increased during
antiandrogen and estrogen treatment (P = 0.005),
but no subject met criteria for diagnosis of type 2
diabetes. Two trans women using transdermal
estrogen patches (15.4%) were switched to other
Figure 2 (A) Changes in prolactin levels during cyproterone acetate (CA) plus oral or transdermal estrogen treatment. Data
are presented as median; error bars represent 95% confidence interval (CI). Dark grey square: CA plus oral estrogens; light
grey square: CA plus transdermal estrogens. We observed a comparable increase in prolactin levels during both oral and
transdermal estrogen treatment (P < 0.001 and P = 0.002, respectively). (B) Changes in prolactin levels during CA plus
estrogens or CA alone. Data are presented as median; error bars represent 95% CI. Dark grey square: CA plus estrogens;
light grey square: CA alone. We observed an increase in prolactin levels during CA + estrogen treatment (P < 0.001) and
during CA treatment alone (P = 0.009). CA + estrogen treatment induced higher prolactin levels compared with CA treatment
alone (P = 0.01).
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therapies because of skin irritation after 3 and 9
months of treatment, respectively.
Treatment-Related Symptoms
Trans Men
Treatment-related symptoms were investigated
every 3 months in a subsample of trans men
(N = 25). The vast majority of the trans men
reported an increase in sexual desire (Figure 3). T
treatment resulted in variable levels of voice deep-
ening and an increased voice instability (P = 0.024).
About 20% of trans men reported clitoral pain,
with a peak incidence observed at 6 months of
treatment. Symptoms of emotionality decreased
(P = 0.01).
We observed no changes in symptoms of night
sweats, hot flashes, abdominal pain, anxiety, breast
tenderness, irritability, palpitations, joint pain,
muscle soreness, headache, mood swings, fatigue,
concentration difficulties, memory, or sleep-
related problems (data not shown).
TransWomen
We examined treatment-related symptoms every
3 months in a subsample of trans women
(N = 30) treated with 50 mg of CA daily in com-
bination with estrogens from the start. A signifi-
cant increase in breast tenderness, emotionality,
low sexual desire, and hot flashes was observed
(P < 0.001, P = 0.001, P < 0.001, and P = 0.02,
respectively) (Figure 3).
We found no changes in night sweats, abdomi-
nal pain, anxiety, irritability, palpitations, skin
dryness, joint pain, muscle soreness, headache,
Table 3 Physical changes in trans persons
Trans men (N = 53) Trans women (N = 53)
Intramuscular T
undecanoate
(N = 53) P
Oral
estrogens
(N = 40) P
Transdermal
estrogens
(N = 13) P
Weight (kg)
Baseline 68.4 ± 15.5 0.01 73.3 ± 13.8 0.10 82.1 ± 13.1 0.99
12 months 70.6 ± 13.2 74.6 ± 14.3 82.1 ± 11.6
BMI (kg/m2)
Baseline 24.8 ± 5.3 0.01 23.1 ± 4.2 0.42 26.1 ± 3.5 0.91
12 months 25.6 ± 4.4 23.7 ± 4.4 26.1 ± 3.4
Total body fat mass (kg)
Baseline 22.9 ± 11.4 <0.001 15.4 ± 7.4 <0.001 16.6 ± 5.4 0.01
12 months 19.9 ± 9.7 20.0 ± 8.1 18.7 ± 4.6
Total body lean mass (kg)
Baseline 43.0 ± 6.6 <0.001 5.6 ± 7.5 <0.001 62.6 ± 9.3 0.02
12 months 48.3 ± 5.6 5.3 ± 8.0 59.7 ± 8.1
Waist circumference (cm)
Baseline 80.3 ± 13.6 0.74 81.2 ± 10.1 0.21 91.6 ± 11.1 0.50
12 months 80.1 ± 11.2 79.7 ± 10.5 90.9 ± 10.1
Hip circumference (cm)
Baseline 97.3 ± 10.5 0.02 94.2 ± 9.3 <0.001 96.9 ± 7.8 0.07
12 months 95.4 ± 9.2 98.1 ± 9.3 100.4 ± 7.1
Waist–hip ratio
Baseline 0.82 ± 0.09 0.03 0.9 ± 0.1 <0.001 0.94 ± 0.06 0.07
12 months 0.84 ± 0.08 0.8 ± 0.1 0.91 ± 0.07
Breast circumference (cm)*
Baseline — — 92.9 ± 10.0 0.03 98.2 ± 9.0 0.09
12 months 95.7 ± 11.2 101.2 ± 9.0
Systolic blood pressure (mm Hg)
Baseline 111.5 ± 12.6 0.05 125.1 ± 13.8 0.005 131.6 ± 15.8 0.47
12 months 115.6 ± 11.7 118.8 ± 13.9 128.8 ± 15.5
Diastolic blood pressure (mm Hg)
Baseline 70.2 ± 10.5 0.18 76.8 ± 10.8 0.32 76.7 ± 9.0 0.43
12 months 72.5 ± 9.2 75.7 ± 10.6 79.7 ± 9.3
Ferriman and Gallwey score
Baseline 0 (0–2) <0.001 — — — —
12 months 10 (6–16)
Acne score
Baseline 2 (0–5) <0.001 2 (0–7) <0.001 0 (0–0) 1.0
12 months 7.5 (2–11.8) 0 (0–0) 0 (0–0)
*Based on subsample (n = 20)
Data are presented as mean ± standard deviation or median (first to third quartiles) in case of non-Gaussian distribution; P value results from paired t-test or
Wilcoxon signed-rank test in case of non-Gaussian distribution
BMI = body mass index
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Figure 3 Prevalence of treatment-related symptoms in trans men (A) and trans women (B)
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mood swings, fatigue, concentration difficulties,
memory, or sleep-related problems (data not
shown).
There were no significant differences in the
presence of treatment-related symptoms at the
3-month time point between trans women treated
with oral or transdermal estrogen. No significant
differences were observed at the 3-month time
point between trans women treated with CA plus
estrogens from start compared with those initially
treated with CA alone (data not shown), except
for a higher prevalence of breast tenderness in
those women treated with CA plus estrogens
(P = 0.001).
Discussion
We presented the first multicenter prospective
study describing the effects of the current CHT
on hormonal and clinical changes, side effects,
and adverse events in trans men and trans
women. The main findings of our study were that
our therapies (injections with T undecanoate
every 3 months in trans men and 50 mg CA plus
either 4 mg oral EV or 100 μg/24 hours trans-
dermal 17-β E2 daily in trans women) were effec-
tive and safe. The majority of trans persons had
desired levels of sex steroids according to the
Endocrine Society Guidelines [1] and developed
the secondary sex characteristics of the desired
sex. Trans men experienced cessation of menses
and developed a male body habitus with an
android pattern of fat distribution, a deepening of
the voice, an increase in lean mass, male pattern
baldness, and both facial and body hair. Trans
women experienced an increase in fat mass with a
gynoid pattern of fat distribution and an increase
in breast circumference.
None of the trans persons experienced severe
adverse events such as cardiovascular events or
death. These findings are in line with previous
reports that demonstrated T treatment for trans
men was effective and relatively safe in the short
term [17–19]. The results in trans women confirm
a recent study [10] showing a low risk for adverse
events at short-time follow-up but contrast earlier
reports that have indicated a high incidence of
venous thrombosis and/or pulmonary embolism
during the first year of CHT [17,19]. Current
treatment modalities in trans women, including
the avoidance of EE usage and using transdermal
estrogens in older trans women, may therefore
be less detrimental to the coagulation system.
Indeed, Toorians and colleagues [20] described a
higher activated protein C resistance with oral EE
compared with oral EV and transdermal 17-β E2
usage. In addition, Van Kesteren et al. [17]
reported a decreased incidence of venous throm-
bosis with the use of transdermal estrogens in
older trans women.
Similar to Mueller and colleagues [18], we
observed a small but significant increase in systolic
blood pressure during T therapy. However, con-
sidering the small increase (about 3.5%) we
observed, it is likely that sample sizes in other
studies [21,22] were too small to detect a statisti-
cally significant difference. Importantly, no subject
developed a clinically significant blood pressure
increase during our study observation. T treat-
ment also increased liver enzymes in our study,
similar to the study from Mueller and colleagues
[18], although the clinical relevance of this finding
remains to be determined.
Previous studies have not investigated system-
atically the treatment-related symptoms during T
therapy in trans men. However, the majority of
trans men reported an increase in voice instability,
acne, and sexual desire. Most acne cases were mild,
and none was severe or very severe according to
the GAGS. Nevertheless, about a third of our
patients underwent acne treatment, indicating that
even mild and moderate acne lesions were clini-
cally relevant.
One trans woman discontinued treatment
because of depression. Indeed, it has been previ-
ously reported that CHT increases depression risk
[19]. However, others show that CHT lowers
anxiety and depression scores possibly due to
improvements in mental health after initiation of
cross-sex reassignment therapy [23]. Similar to
others [17,19], we found a transient elevation of
the liver enzymes during antiandrogen and estro-
gen treatment, although, generally, a decrease in
liver enzymes is observed [24].
Concerning the risk for hyperprolactinemia
during CHT in trans women, our findings sub-
stantiate most other studies showing an increase in
prolactin levels during administration of CA com-
bined with estrogen therapy [1,17,25–28] and CA
alone [25,27]. However, our previous retrospective
follow-up studies do not show a further increase in
the long term [5,29]. Moreover, the clinical
relevance of increased prolactin levels during
CHT remains undetermined. Although a few case
reports of prolactinomas have been reported fol-
lowing CHT, none was reported in large follow-up
studies, perhaps suggesting a low risk associated
with CHT.
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Trans women also reported treatment-related
symptoms. Although some of them, such as breast
tenderness and low sexual desire, were well-known
from our clinical practice, subjects unexpectedly
reported a significant increase in hot flashes during
antiandrogen and estrogen treatment. Because we
did not use validated questionnaires or objective
measurements to analyze these symptoms, further
exploration and characterization are needed.
Investigation of cardiovascular risk factors
during CHT is important as recent studies show
that trans women have an increased cardiovascular
morbidity [30] and mortality [11,31] compared
with the general population. Similar to previously
published studies using EE plus CA, we found a
reduction in LDL-C and an increase in fat mass
and fasting insulin during the first year of CHT in
trans women [21,32]. Estrogen therapy increases
removal of LDL apolipoprotein B-100 [33], but
the pathophysiological mechanism of increased
insulin resistance during antiandrogen and estro-
gen therapy is not fully understood. CHT induces
important changes in body composition, with an
increase in fat mass, which may affect glucose
metabolism. Sex steroids may also exert direct
effects, as acute T withdrawal in men decreases
insulin sensitivity in the absence of any detectable
changes in body composition [34]. Augmentation
of E2 to supraphysiological levels may also induce
insulin resistance through liver hyperinsulinemia
and reduced GLUT 4 expression within the
muscles [35].
In line with Dittrich and colleagues [10], we
observed no increase in body weight, triglycerides,
or blood pressure in trans women. These findings
differ from a previously published study using EE
plus CA [21] and are likely to be related to differ-
ences in type of estrogen used. Different types of
estrogen exert divergent metabolic effects. EE has
a stronger hepatic impact due to its 17α-ethinyl
group, which prevents the inactivation of the mol-
ecule and results in a slower metabolism [36,37].
Additionally, the higher estrogen dosage in the
study by Elbers and colleagues [21] may also con-
tribute to differences in these health outcomes.
HDL-C decreased in trans women (in both oral
and transdermal group), which was somewhat
unexpected under estrogen therapy. A potential
explanation for these findings may be found in the
progestagenic effects of CA, as progestogens
decrease HDL-C concentrations [33]. Decreased
HDL-C levels have been previously shown in
trans women using transdermal estrogen therapy
[38,39]. Because the transdermal route avoids the
first pass effect of the liver, it may have different
metabolic effects than oral estrogen therapy.
Decreased triglycerides were also observed with
transdermal but not oral estrogen therapy. In addi-
tion, trans women using oral EV showed signifi-
cantly higher E1/E2 ratio than those using
transdermal therapy. A lower E1/E2 ratio has been
reported in postmenopausal women receiving
transdermal hormone replacement therapy [40].
No other differences were observed between these
two modes of estrogen treatment, suggesting both
are equally effective.
T undecanoate treatment decreased fat mass
but induced a less favorable lipid profile and an
android pattern of fat distribution in trans men.
Although these changes were also seen in studies
using two or three weekly injections of intramus-
cular T esters [41,42], most of the evidence
suggests that T treatment is relatively safe at short-
and medium-term follow-up [17–19]. However,
outcome studies in trans men are generally per-
formed in much smaller sample sizes and at
younger ages compared with trans women. Large,
long-term (>20 years) follow-up studies are
needed to investigate the cardiovascular safety of
T therapy in trans men.
As previously described [12], the age and sex
ratio differed significantly between our two
centers. This age difference should be kept in
mind in future outcome studies as older age may
be associated with a worse cardiovascular outcome
[43].
The strengths of the present study were its rela-
tively large sample size compared with most other
prospective studies; the use of widely prescribed
(but scientifically not well documented) treatment
modalities; our detailed description of adverse
events, side effects, and treatment-related symp-
toms; and the use of a mass spectrometry-based
methodology to measure serum sex steroid levels
in trans persons. Although we did not use a vali-
dated questionnaire to measure treatment-related
symptoms, we were the first to examine these
symptoms systematically. Validation of such a
questionnaire may be valuable for future studies as
no standardized assessment of symptoms exists
presently. Secondly, our treatment protocol was to
administer oral EV to trans women younger than
45 years and transdermal estrogen therapy to those
over 45 years. This age discrepancy may have
influenced the difference in treatment response
between the two groups. In addition, some trans
women initially received CA alone without con-
comitant estrogen use. This may have influenced
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our results, although no significant differences
were observed between these two groups. More-
over, the lack of difference between the groups
may indicate that most relevant changes occur
during the first 9 months of CHT. Thirdly, we did
not have a blinded clinician to determine the clini-
cal effects of the treatment, which may possibly
induce a bias. Finally, we described average differ-
ences associated with each treatment, but we
observed large between-subject differences in
clinical outcome measures, which may be due to
differences in sex steroid metabolism or sensitivity.
Conclusion
We observed that our current treatment modali-
ties in both trans men and women were effective
and carried a low risk for side effects and adverse
events at short-time follow-up.
Acknowledgments
The authors are indebted to Griet De Cuypere, MD,
PhD; Gunter Heylens, MD; Els Elaut, MSc; Birgit
Van Hoorde, MSc; Steven Weyers, MD, PhD; Piet
Hoebeke, MD, PhD; and Stan Monstrey, MD, PhD
for referral of participants. We thank Jens Jacobeit,
MD (Endokrinologikum, Hamburg, Germany), Mick
Van Trotsenburg and Martin den Heijer (Vrije
Universiteit, Amsterdam, the Netherlands) for their
contribution to the development of the ENIGI endo-
crinological protocol.
Corresponding Author: Katrien Wierckx, MD,
Department of Endocrinology, De Pintelaan 185 9000
Ghent, Belgium. Tel: 0032 9 332 19 66; Fax: 0032 9 332
38 00; E-mail: katrien.wierckx@ugent.be
Conflict of Interest: The author(s) report no conflicts of
interest.
Statement of Authorship
Category 1
(a) Conception and Design
Katrien Wierckx; Guy T’Sjoen; Thomas Schreiner;
Alessandra Fisher
(b) Acquisition of Data
Katrien Wierckx; Eva Van Caenegem; Kaatje Toye;
Thomas Schreiner
(c) Analysis and Interpretation of Data
Katrien Wierckx; Guy T’Sjoen; Jean Marc
Kaufman; Ira Haraldsen
Category 2
(a) Drafting the Manuscript
Katrien Wierckx; Guy T’Sjoen
(b) Revising It for Intellectual Content
Katrien Wierckx; Eva Van Caenegem; Thomas
Schreiner; Ira Haraldsen; Alessandra Fisher; Kaatje
Toye; Jean Marc Kaufman; Guy T’Sjoen
Category 3
(a) Final Approval of the Completed Manuscript
Katrien Wierckx; Eva Van Caenegem; Thomas
Schreiner; Ira Haraldsen; Alessandra Fisher; Kaatje
Toye; Jean Marc Kaufman; Guy T’Sjoen
References
1 Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal
HA, Gooren LJ, Meyer WJ III, Spack NP, Tangpricha V,
Montori VM. Endocrine treatment of trans persons: An Endo-
crine Society clinical practice guideline. J Clin Endocrinol
Metab 2009;94:3132–54.
2 Gooren L. Care of transsexual persons. N Engl J Med
2011;364:1251–7.
3 Moore E, Wisniewski A, Dobs A. Endocrine treatment of trans
people. A review of treatment regimes, outcomes and adverse
effects. J Clin Endocrinol Metab 2003;88:3467–73.
4 Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of
transsexuals with cross-sex hormones: Extensive personal
experience. J Clin Endocrinol Metab 2008;93:19–25.
5 Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G,
Heylens G, T’Sjoen G. A long-term evaluation of cross-sex
hormone treatment in transsexual persons. J Sex Med
2012;9:2641–51.
6 Schlatterer K, Yassouridis A, von Werder K, Poland D,
Kemper J, Stalla G. A follow-up study for estimating the effec-
tiveness of a cross-gender hormone substitution therapy on
transsexual patients. Arch Sex Behav 1998;27:475–92.
7 Prior J, Vigna Y, Watson D. Spironolactone with physiological
female steroids for presurgical therapy of male-to-female
transsexualism. Arch Sex Behav 1989;18:49–57.
8 Tangpricha V, Ducharme SH, Barber TW, Chipkin SR.
Endocrinologic treatment of gender identity disorders. Endocr
Pract 2003;9:12–21.
9 Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclaire S,
Barret J. Predictive markers for mammoplasty and a compari-
son of side effect profiles in trans women taking various
hormonal regimens. J Clin Endocrinol Metab 2012;97:
4422–8.
10 Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW,
Mueller A. Endocrine treatment of male-to-female transsexu-
als using gonadotropin-releasing hormone agonist. Exp Clin
Endocrinol Diabetes 2005;113:586–92.
11 Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van
Trotsenburg MA, Gooren LJ. A long-term follow-up study of
mortality in transsexuals receiving treatment with cross-sex
hormones. Eur J Endocrinol 2011;164:635–42.
12 Kreukels BP, Haraldsen IR, Richter-Appelt H, Gijs L,
Cohen-Kettenis P. A European network for the investigation
of gender incongruence: The ENIGI initiative. Eur Psychiatry
2012;27:445–50.
13 Dreno B, Khammari A, Orain N, Noray C, Mérial-Kieny C,
Méry S, Nocera T. ECCA grading scale: An original validated
acne scar grading scale for clinical practice in dermatology.
Dermatology 2007;214:46–51.
14 Ferriman D, Gallwey J. Clinical assessment of body hair
growth in women. Clin Endocrinol Metab 1966;21:1440–7.
15 Norwood OT. Male pattern baldness: Classification and inci-
dence. South Med J 1975;68:1359–65.
2010 Wierckx et al.
J Sex Med 2014;11:1999–2011
16 Fiers T, Casetta B, Bernaert B, Vandersypt E, Debock M,
Kaufman JM. Development of highly sensitive method for the
quantification of estrone and estradiol in serum by liquid chro-
matography tandem mass spectrometry without derivatization.
J Chromatogr B Analyt Technol Biomed Life Sci 2012;893:57–
62.
17 Van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mor-
tality and morbidity in trans subjects treated with cross-sex
hormones. Clin Endocrinol 1997;47:337–42.
18 Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich
R. Long-term administration of testosterone undecanoate
every 3 months for testosterone supplementation in female-to-
male transsexuals. J Clin Endocrinol Metab 2007;92:3470–5.
19 Asscheman H, Gooren LJG, Eklund PL. Mortality and
morbidity in trans patients with cross-gender treatment.
Metabolism 1989;38:869–73.
20 Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ,
Tans G, Gooren LJ, Rosing J. Venous thrombosis and changes
of hemostatic variables during cross-sex treatment in trans-
sexual people. J Clin Endocrinol Metab 2003;88:5723–9.
21 Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H,
Seidell JC, Gooren LJ. Effects of sex steroids on components
of the insulin resistance syndrome in transsexual subjects. Clin
Endocrinol 2003;58:562–71.
22 Giltay EJ, Lambert J, Gooren LJ, Elbers JM, Steyn M,
Stehouwer CD. Sex steroids, insulin, and arterial stiffness in
women and men. Hypertension 1999;34:590–7.
23 Gómez-Gil E, Zubiaurre-Elorza L, Esteva I, Guillamon A,
Godás T, Cruz Almaraz M, Halperin I, Salamero M.
Hormone-treated transsexuals report less social distress,
anxiety and depression. Psychoneuroendocrinology 2012;37:
662–70.
24 Mueller A, Binder H, Cupisti S, Hoffmabb I, Beckmann MW,
Dittirch R. Effects on the male endocrine system of long-term
treatment with gonadotropin-releasing hormone agonists and
estrogens in male-to-female transsexuals. Horm Metab Res
2006;38:183–7.
25 Gooren LJ, Harmsen-louman W, Van Kessel H. Follow-up of
prolactin levels in long-term oestrogen-treated male-to-female
transsexuals with regard to prolactinoma induction. Clin
Endocrinol 1985;22:201–7.
26 Asscheman H, Gooren LJ, Assies J, Smits JPH, De Slegte R.
Prolactin levels and pituitary enlargement in hormone-treated
male-to-female transsexuals. Clin Endocrinol 1988;25:583–8.
27 Gooren L, Van Der Veen EA, Kessel H. Modulation of pro-
lactin secretion by gonadal steroids in men. In: McLeod RM,
Scampagmani U, eds. Central and peripheral regulation of
prolactin function. New York: Raven Press; 1980:365–9.
28 Schlatterer K, Yassouridis A, von Werder K, Poland D,
Kemper J, Stalla GK. A follow-up study for estimating the
effectiveness of a cross-gender hormone substitution therapy
on transsexual patients. Arch Sex Behav 1988;27:475–92.
29 De Cuypere G, T’Sjoen G, Beerten R, Selvaggi G, De Sutter
P, Hoebeke P, Monstrey S, Vansteenwegen A, Rubens R.
Sexual and physical health after sex reassignment surgery. Arch
Sex Behav 2005;34:679–90.
30 Wierckx K, Elaut E, Declerq E, Heylens G, Decuypere G,
Taes Y, Kaufman JM, T’sjoen GR. Prevalence of cardiovascu-
lar disease and cancer during CHT in a large cohort of trans
persons: A case control study. Eur J Endocrinol 2013;169:
471–8.
31 Dhejne C, Lichtenstein P, Boman M, Johansson A, Langström
N, Landén M. Long-term follow-up of transsexuals’ persons
undegoing sex reassignment surgery: Cohort study in Sweden.
PLoS ONE 2011;6:e16885. doi: 10.1371/journal.pone.
0016885.
32 Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine
RJ. Induction of insulin resistance by androgens and estrogens.
J Clin Endocrinol Metab 1994;79:265–71.
33 Wang X, Magkos F, Mittendorfer B. Sex differences in lipid
and lipoprotein metabolism: It’s not just about sex hormones.
J Clin Endocrinol Metab 2011;96:885–93.
34 Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N,
Hayes FJ. Acute sex steroid withdrawal reduces insulin
sensitivity in healthy men with idiopathic hypogonadotropic
hypogonadism. J Clin Endocrinol Metab 2007;92:4254–9.
35 Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estro-
gens in control of energy balance and glucose homeostasis.
Endocr Rev 2013;34:309–38.
36 Ågren UM, Anttila M, Mäenpää-Liukko K, Rantala ML,
Rautiainen H, Sommer WF, Mommers E. Effects of a mono-
phasic combined oral contraceptive containing nomegestrol
acetate and 17β-oestradiol compared with one containing
levonorgestrel and ethinylestradiol on haemostasis, lipids and
carbohydrate metabolism. Eur J Contracept Reprod Health
Care 2011;16:444–57.
37 Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P,
Nakamura RM, Brenner PF, Mishell DR Jr. Comparison of
pharmacodynamic properties of various estrogen formulations.
Am J Obstet Gynecol 1982;144:511–8.
38 Giltay EJ, Gooren LJ, Emeis JJ, Kooistra T, Stehouwer CD.
Oral ethinyl estradiol, but not transdermal 17beta-estradiol,
increases plasma C-reactive protein levels in men. Thromb
Haemost 2000;84:359–60.
39 Giltay EJ, Gooren LJ, Emeis JJ, Kooistra T, Stehouwer CD.
Oral, but not transdermal, administration of estrogens lowers
tissue-type plasminogen activator levels in humans without
affecting endothelial synthesis. Arterioscler Thromb Vasc Biol
2000;20:1396–403.
40 Scott RT Jr, Ross B, Anderson C, Archer DF. Pharmacokinet-
ics of percutaneous estradiol: A crossover study using a gel and
a transdermal system in comparison with oral micronized
estradiol. Obstet Gynecol 1991;77:758–64.
41 Giltay EJ, Elbers JM, Gooren LJ, Emeis JJ, Kooistra T,
Stehouwer CD. Visceral fat accumulation is an important
determinant of PAI-levels in young, non-obese men and
women: Modulation by cross-sex hormone administration.
Arterioscler Thromb Vasc Biol 1998;18:1719–22.
42 Van Caenegem E, Wierckx K, Taes Y, Dedecker D,
Van de peer F, Toye K, Kaufman JM, T’sjoen G. Bone mass,
bone geometry, and body composition in female-to-male
transsexual persons after long-term cross-sex hormonal
therapy. J Clin Endocrinol Metab 2012;97:2503–11.
43 Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G,
Taes Y, Kaufman JM, T’Sjoen G. Prevalence of cardiovascular
disease and cancer during cross-sex hormone therapy in a large
cohort of trans persons: A case-control study. Eur J Endocrinol
2013;169:471–8.
Endocrine Treatment of Trans Persons 2011
J Sex Med 2014;11:1999–2011
